PubRank

Ishwarlal Jialal

Author PubWeight™ 152.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2007 2.84
2 Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 2005 2.72
3 Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006 2.65
4 Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 2.50
5 Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010 2.39
6 Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008 2.29
7 High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008 2.23
8 C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003 2.09
9 Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006 2.06
10 Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 2011 1.91
11 Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008 1.86
12 High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007 1.85
13 Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007 1.84
14 Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol 2012 1.67
15 Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem 2005 1.53
16 Oxidative stress and atherosclerosis. Pathophysiology 2006 1.52
17 Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008 1.51
18 Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr 2005 1.51
19 Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes 2005 1.50
20 The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2008 1.48
21 Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab 2010 1.45
22 Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol 2004 1.43
23 Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006 1.42
24 Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009 1.40
25 Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med 2016 1.39
26 CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2010 1.37
27 Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 2011 1.34
28 C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003 1.34
29 Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 2006 1.32
30 Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med 2007 1.30
31 The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 2006 1.28
32 Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013 1.26
33 Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009 1.26
34 Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab 2011 1.25
35 C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007 1.25
36 Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes 2002 1.24
37 Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr 2002 1.23
38 Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005 1.23
39 C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2008 1.21
40 C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol 2006 1.21
41 Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab 2003 1.19
42 Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004 1.17
43 Innate immunity genes influence the severity of acute appendicitis. Ann Surg 2004 1.16
44 C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 2011 1.15
45 Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr 2007 1.14
46 Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005 1.14
47 CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 2008 1.10
48 Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005 1.10
49 Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol 2013 1.10
50 Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010 1.06
51 CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006 1.04
52 Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism 2010 1.02
53 Failure of vitamin E in clinical trials: is gamma-tocopherol the answer? Nutr Rev 2005 1.01
54 Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005 1.01
55 Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol 2011 1.01
56 C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005 1.00
57 High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism 2008 1.00
58 Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr 2002 0.99
59 Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr 2006 0.98
60 Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 2007 0.98
61 Coenzyme Q10 supplementation and heart failure. Nutr Rev 2007 0.98
62 Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem 2010 0.97
63 Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004 0.97
64 Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci 2004 0.97
65 Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007 0.96
66 TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice. Lab Invest 2010 0.96
67 Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism 2004 0.96
68 Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol 2012 0.95
69 Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem 2011 0.95
70 C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem 2008 0.94
71 Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 2006 0.94
72 Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med 2004 0.93
73 Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2008 0.93
74 C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem 2011 0.93
75 Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009 0.93
76 Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol 2009 0.92
77 Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem 2008 0.92
78 Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med 2005 0.92
79 C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 2009 0.92
80 The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 2005 0.92
81 Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003 0.91
82 Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010 0.91
83 C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol 2006 0.90
84 Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002 0.90
85 Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord 2012 0.90
86 High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Clin Chem 2007 0.88
87 Hyperhomocysteinemia in Asian Indians living in the United States. J Clin Endocrinol Metab 2003 0.88
88 Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. Cytokine 2009 0.88
89 C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol 2008 0.88
90 Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol 2004 0.87
91 Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord 2014 0.87
92 Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 2010 0.87
93 A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. J Am Coll Nutr 2008 0.86
94 Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 2006 0.85
95 Dysfunctional endothelial progenitor cells in metabolic syndrome. Exp Diabetes Res 2011 0.85
96 Measurement of beta1- and beta2-globulins improves detection of M-spikes on high-resolution electrophoresis. Clin Chem 2003 0.84
97 Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 2006 0.84
98 Amelioration in wound healing in diabetic toll-like receptor-4 knockout mice. J Diabetes Complications 2013 0.84
99 Remnant lipoproteins: measurement and clinical significance. Clin Chem 2002 0.84
100 Effect of orange juice and beverage with phytosterols on cytokines and PAI-1 activity. Clin Nutr 2011 0.84
101 Effects of epigallocatechin gallate on regulatory T cell number and function in obese v. lean volunteers. Br J Nutr 2010 0.83
102 C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase. Clin Chem 2010 0.82
103 The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev 2006 0.82
104 Increased neutrophil count in nascent metabolic syndrome. Metab Syndr Relat Disord 2013 0.82
105 Asymptomatic isolated human glycerol kinase deficiency associated with splice-site mutations and nonsense-mediated decay of mutant RNA. Pediatr Res 2006 0.81
106 Endothelial progenitor cell status in metabolic syndrome. Metab Syndr Relat Disord 2010 0.81
107 Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 2008 0.81
108 The effect of weight loss and dietary fatty acids on inflammation. Curr Atheroscler Rep 2006 0.80
109 Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002 0.80
110 Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am J Clin Pathol 2007 0.80
111 RRR-alpha-tocopherol decreases the expression of the major scavenger receptor, CD36, in human macrophages via inhibition of tyrosine kinase (Tyk2). Atherosclerosis 2004 0.79
112 Increased expression of Fc-γ receptors on monocytes in patients with nascent metabolic syndrome. J Clin Endocrinol Metab 2013 0.79
113 Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol 2003 0.79
114 CRP induces hypertension in animal models: homo sapiens says no. Hypertens Res 2011 0.79
115 Is vitamin C an antiinflammatory agent? Am J Clin Nutr 2006 0.79
116 The role of the laboratory in the diagnosis of the metabolic syndrome. Am J Clin Pathol 2009 0.78
117 Modulation of endothelial progenitor cell number and function with n-3 polyunsaturated fatty acids. Atherosclerosis 2013 0.78
118 Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep 2011 0.78
119 A randomized placebo-controlled crossover trial of aloe vera on bioavailability of vitamins C and B(12), blood glucose, and lipid profile in healthy human subjects. J Diet Suppl 2010 0.78
120 alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. Diabetes Care 2002 0.78
121 Autoantibodies to oxidized low-density lipoprotein in patients with type 2 diabetes mellitus. Clin Chim Acta 2002 0.78
122 Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus. Curr Diab Rep 2014 0.77
123 Statin therapy for the metabolic syndrome: the evidence base. Metab Syndr Relat Disord 2009 0.77
124 The role of C-reactive protein activation of nuclear factor kappa-B in the pathogenesis of unstable angina. J Am Coll Cardiol 2006 0.77
125 Hyperhomocysteinemia measured by immunoassay: a valid measure of coronary artery atherosclerosis. Arch Pathol Lab Med 2004 0.77
126 Laboratory diagnosis of ethylene glycol poisoning: the cup is half full? Am J Clin Pathol 2011 0.77
127 Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Metab Syndr Relat Disord 2012 0.77
128 Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity. Arch Pathol Lab Med 2008 0.77
129 Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol 2012 0.77
130 High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005 0.76
131 Thyrotropin receptor antibody assays: clinical utility. Am J Clin Pathol 2013 0.75
132 Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Curr Atheroscler Rep 2002 0.75
133 Bariatric surgery for the metabolic syndrome: magic bullet or not? Metab Syndr Relat Disord 2012 0.75
134 Strategies to lower low-density lipoprotein cholesterol in metabolic syndrome: averting the diabetes risk. Metab Syndr Relat Disord 2013 0.75
135 Use of HbA1c in the diagnosis of diabetes and prediabetes: sensitivity versus specificity. Metab Syndr Relat Disord 2014 0.75
136 Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord 2010 0.75
137 Therapy and clinical trials. Curr Opin Lipidol 2007 0.75
138 Synthesis and characterization of a novel inhibitor of C-reactive protein-mediated proinflammatory effects. Metab Syndr Relat Disord 2013 0.75
139 The Authors' Reply. Am J Clin Pathol 2015 0.75
140 Therapy and clinical trials. Curr Opin Lipidol 2002 0.75
141 Therapy and clinical trials. Curr Opin Lipidol 2005 0.75
142 Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications. Circulation 2002 0.75
143 Therapy and clinical trials: ezetimibe. Curr Opin Lipidol 2003 0.75
144 Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé. Metab Syndr Relat Disord 2009 0.75
145 Modulation of monocyte-macrophage function with alpha-tocopherol: implications for atherosclerosis. Nutr Rev 2002 0.75
146 Therapy and clinical trials. Curr Opin Lipidol 2003 0.75
147 The cholesterol ester transfer protein inhibitor, anacetrapib. Curr Opin Lipidol 2011 0.75
148 Future directions in clinical vitamin E research: panel discussion B. Ann N Y Acad Sci 2004 0.75
149 Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia? Metab Syndr Relat Disord 2011 0.75
150 Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Am J Cardiol 2002 0.75
151 Lipid management in clinical practice. Curr Opin Lipidol 2009 0.75
152 Statin therapy in acute cardiovascular syndromes. Curr Opin Lipidol 2007 0.75
153 Editorial. Metab Syndr Relat Disord 2007 0.75
154 The tenth anniversary of metabolic syndrome and related disorders. Metab Syndr Relat Disord 2011 0.75